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The last half-decade has seen an explosion in our under-
standing of the molecular basis of normal and abnormal
cardiac electrophysiology. Most intriguing are studies link-
ing specific genetic defects with defined clinical syndromes
(phenotypes) in diseases like the long-QT syndrome
(LQTS) or the Brugada syndrome; these genotype-
phenotype correlations not only point to links between
subcellular phenomena and the electrical behavior of the
whole heart but also suggest mechanisms in more common,
“acquired” arrhythmias. In this issue of the Journal, Smits et
al. (1) provide just such an example in their evaluation of a
large group of patients with the Brugada syndrome.
See page 350
GENETIC HETEROGENEITY IN THE LQTS
Studies of LQTS have demonstrated genetic heterogeneity,
that is, the disease phenotype can arise from mutations in
any one of multiple (probably at least seven) genes (2).
Important direct consequences of these genetic studies have
included:
1) Identification of families with very low penetrance, that
is, including individuals with disease-associated muta-
tions, but “no” clinical phenotype (3). We and others
have suggested that such individuals may, nevertheless,
be at increased risk for torsades during challenge with
QT-prolonging drugs (4–7). The extent to which vari-
ability in our individual genomes predisposes to unusual
responses to pathophysiologic stressors or to drug chal-
lenge remains largely unexplored.
2) HERG has been identified not only as an LQTS disease
gene but also as the predominant target of most drugs
inducing torsades de pointes (8). This finding, in turn,
has led to important changes in the way in which the
pharmaceutical industry and regulatory agencies ap-
proach the problem of potential torsades toxicity by
nonantiarrhythmic drugs (9). More generally, the iden-
tification of a molecular target represents an important
advance in screening out undesirable actions in new
drugs as they are developed.
3) It has long been recognized that individuals with the
LQTS may not fit the “typical” clinical description of
events with adrenergic stress or “failure to shorten the
QT interval” with exercise. This phenotypic heteroge-
neity has now been partially resolved with the observa-
tions that the details of the clinical phenotype may be
driven largely by the specific gene (or, conceivably, the
specific region within that gene product) (10) affected.
These findings, in turn, have important implications for
evolving thinking about subtype-specific presentations in
LQTS (11,12), as well as possible subtype-specific ther-
apies, such as the preference for beta-blockade in LQT1
and the thought (as yet unconfirmed in clinical trials)
that sodium channel block may play a special role in
LQT3 (13,14).
GENETIC AND PHENOTYPIC
HETEROGENEITY IN THE BRUGADA SYNDROME
The entity of right precordial J-point elevation, no under-
lying structural cardiac abnormality and “idiopathic” ven-
tricular fibrillation (VF) (15) was recognized as a syndrome
by Brugada and Brugada in the early 1990s (16). As in
LQTS, affected individuals who do not display the manifest
electrocardiographic features until challenge with a drug
were recognized early on; in the case of the Brugada
syndrome, the drug challenge required to elicit the electro-
cardiogram phenotype was not QT-prolonging drugs but
sodium channel block (17). The recognition of the relation-
ship between Brugada syndrome and sodium channel block-
ers provided an initial clue that led to identification of
mutations in SCN5A—encoding the cardiac sodium chan-
nel—in individuals, and subsequently in kindreds, with the
Brugada syndrome (18,19). Moreover, genetic heterogene-
ity has been demonstrated: kindreds in whom linkage
analysis has ruled out the SCN5A locus have been identified
(20). Smits et al. (1) now extend the parallels between
LQTS and the Brugada syndrome by reporting phenotypic
differences between 23 patients with Brugada syndrome
related to mutations in the coding regions of SCN5A and 54
individuals in whom such mutations were not identified.
The SCN5A-related patients had greater defects in impulse
propagation (greater QRS prolongations with sodium chan-
nel blocker challenge, and longer baseline, longer PR and
HV intervals) than non–SCN5A-related patients. The study
is limited by the fact that we do not know what the
mutations are in the non–SCN5A-related group and
whether they are, in turn, all in a single locus; they could
even be in regions that regulate the level of expression of
SCN5A itself. Nevertheless, the findings suggest greater
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defects in the function of the fast sodium channel in
individuals with SCN5A coding region mutations and raise
the possibility, as suggested by the authors, that, in the
future, it may be possible to use clinical criteria as a first step
in identifying the specific genetic locus affected. Ultimately,
it may even be possible to devise gene-specific therapies,
although this seems much further off and awaits identifica-
tion of other disease genes in this syndrome.
A RANGE OF FUNCTIONAL DEFECTS
IN THE CARDIAC SODIUM CHANNEL
Mutations in SCN5A also cause the LQT3 subtype of
LQTS, as well as isolated conduction system disease (21).
Initial in vitro characterization of LQT3-related mutations
demonstrated a persistent late inward current through
mutant sodium channels. Because this behavior was not
present in wild-type channels, it has been termed a “gain of
function” (to contrast it with potassium channel defects in
other forms of LQTS that largely result from a “loss of
function”). However, the function that is “gained” in LQT3
is actually a mutation-imposed loss of normal fast inactiva-
tion. More recently, other LQT3-related SCN5A muta-
tions, which do not result in persistent noninactivating
current, have been identified (22), demonstrating that,
rather than considering simple “gain” or “loss” of function as
the mechanisms in LQTS, the derangements in protein
function imposed by mutations should be considered more
globally. While in vitro characterization of Brugada
syndrome-related mutations is not as far advanced as in
LQTS, sufficient evidence has been accumulated to impli-
cate reduction in sodium current—through diverse mecha-
nisms—as the underlying defect in the Brugada syndrome.
These mechanisms include defective trafficking of sodium
channels to the cell surface (i.e., fewer channels at the cell
surface) (23), mutations that result in nonfunctional pro-
teins (18) and mutations that generate proteins whose
occupancy of an “intermediate” inactivated state is en-
hanced, resulting in fewer sodium channels available at
normal heart rates (24,25). Indeed, the Amsterdam group
(19,26) has described a large kindred with both the Brugada
and LQT3 phenotypes arising from a single mutation in the
C-terminus of SCN5A of the sodium channel protein. The
mutation, 1795insD, not only destabilizes fast inactivation
but also promotes slow inactivation, thereby explaining the
dual phenotype and reinforcing the idea that the terms “gain
of function” or “loss of function” are incomplete descriptors,
at best, of the molecular dysfunction that causes these
interesting diseases. The way in which specific mutations
give rise to LQTS, Brugada syndrome, conduction system
disease or combinations remains an exciting area in molec-
ular electrophysiology. One intriguing report suggests that
the extent to which some Brugada syndrome mutations
reduce sodium channel availability may be strongly modu-
lated by the presence or absence, in a particular patient, of
common DNA variants (polymorphisms and not disease-
associated mutations) in SCN5A (27).
WHAT MIGHT THE OTHER
BRUGADA SYNDROME DISEASE GENE(S) BE?
Studies of right ventricular epicardial action potentials and
their response to sodium channel block have provided a nice
explanation of the way in which loss of sodium channel
function might translate into the Brugada phenotype
(17,28). In brief, epicardial cells have a very prominent
phase 1 “notch,” driven by the presence of a large transient
outward current (ITO). The end of phase 1 can be viewed as
a balance between waning inward current through sodium
channels and ITO. Reduction in sodium current in the
Brugada syndrome is thought to disrupt this balance,
driving the end of phase 1 to much more negative potentials.
When this happens, phase 2 simply does not occur, and the
action potential becomes very abbreviated. This effect can be
heterogeneous, resulting in cells with very short action poten-
tials adjacent to those with normal ones, the ideal breeding
ground for the reentrant excitation underlying VF.
Given this framework for understanding the way in
which mutations can cause the Brugada phenotype, it is, of
course, tempting to speculate on what the nature of the
other disease gene(s) might be. One obvious possibility is
mutations that increase the transient outward current, to
upset the balance between ITO and INa. Lesions in other ion
channel genes are also plausible. However, inspection of the
genomic sequence of 3p22-25, one “non–SCN5A” chromo-
somal locus linked to the Brugada syndrome, does not reveal
any recognized ion channel, implying that ion channels with
as-yet-unrecognized structures remain to be identified or
that mutations arise in other elements regulating channel
function (e.g., ancillary subunits, chaperone proteins, an-
choring proteins, kinases, regulatory genes or regions). It
will be especially interesting to identify the mechanisms
whereby non–SCN5A-related patients demonstrate the Bru-
gada phenotype and yet appear to have much less of a
problem with impulse propagation.
VARIABLE “ANTIFIBRILLATORY RESERVE”
I believe that the greatest importance of defining the
molecular mechanisms in entities like LQTS or the Brugada
syndrome lies not so much in the management of individual
patients but in understanding the way in which sometimes
subtle and sometimes not-so-subtle functional defects in
individual gene products may translate into variable risk for
VF. Several pieces of evidence, taken together, suggest the
notion that an individual’s risk for VF during “challenge”
with acute myocardial ischemia may be, in part, genetically
determined, in much the same way as clinical response to
“challenge” with QT-prolonging drugs seems determined
by multiple factors, each contributing to overall susceptibil-
ity to torsades by reducing “repolarization reserve” (29).
Moreover, variants (rare mutations or common polymor-
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phisms) in SCN5A and other Brugada syndrome disease
genes are excellent candidates for modifying VF risk. This
evidence includes: 1) manifest loss of sodium channel
function in the Brugada syndrome increases risk for VF; 2)
epidemiologic studies identify a family history of sudden
death as an independent risk factor for sudden death
(30,31); 3) the Cardiac Arrhythmia Suppression Trial dem-
onstrated in the 1980s that treatment with sodium channel
blockers in the recently injured myocardium increased
sudden death risk, especially in patients at risk for recurrent
ischemic episodes (32,33); and 4) in vitro studies report that
the right ventricular epicardium responds to simulated isch-
emia in much the same way as it responds to sodium channel
block, with heterogeneous abbreviation of epicardial action
potentials to promote reentrant excitation (34). Testing the
concept of variable “antifibrillatory reserve” will become possi-
ble as new Brugada syndrome disease genes are identified and
their roles in modulating baseline electrophysiology and its
response to ischemic stress are identified. Ultimately, stratifi-
cation of risk for VF may extend from the clinical predictors we
use now to such new genetic markers (35).
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